SOUTHWEST ONCOLOGY GROUP

西南肿瘤集团

• 批准号: 2086160
• 负责人: THOMAS Patrick MILLER
• 金额: $ 33.62万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-01-01 至 1997-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2086160
• 关键词: Hodgkin's disease; acute leukemia; all trans retinol; bladder neoplasm; bleomycin; breast neoplasms; cancer prevention; carmustine; carotene; chronic myelogenous leukemia; cis platinum compound; clinical trials; colon neoplasms; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytosine arabinoside; daunorubicin; doxorubicin; drug screening /evaluation; etoposide; fluorouracil; gonadotropin releasing factor; head /neck neoplasm; hormone therapy; human subject; human therapy evaluation; interferon alpha; interferon gamma; interleukin 1; interleukin 3; lung neoplasms; lymphoma; melanoma; melphalan; metastasis; mitoxantrone; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer remission /regression; neoplasm /cancer surgery; nephrectomy; nonHodgkin's lymphoma; nutrition related tag; oral leukoplakia; ovary neoplasms; paclitaxel; phosphamide; prednisone; prognosis; quinine; renal cell carcinoma; retinoids; sarcoma; skin neoplasms; suramin; testis neoplasms; tumor necrosis factor alpha; verapamil; vincristine

Funding is requested to support Arizona Cancer Center (University of Arizona) participation in Southwest Oncology Group cooperative cancer clinical research to improve the treatment of cancer in humans. Specific aims and objectives are: 1. To continue to meet our current scientific leadership and core service commitments including: (a) protocol coordination (multiple studies): (b) disease/discipline committee administration; (c reference and repository laboratory administration; (d) group quality assurance and quality control. 2. To continue to promote the rapid integration of promising new research leads, including those developed at the Arizona Cancer Center, into cooperative group testing to improve patient treatment options and patient care. 3. To continue to meet our institutional clinical research commitments in the recruitment of appropriate patients for SWOG studies and all attendant commitments to longterm followup, quality control, etc. 4. To continue to promote community physician and patient awareness and participation in SWOG clinical trials continued support of the Cooperative Group Outreach Program ?CGOP) and other outreach and continuing education programs and activities. 5. To continue efforts to understand factors affecting accrual, particularly those in special populations (eg, minority, elderly, financially disadvantaged), and to implement appropriate interventions where possible.

申请资金支持亚利桑那癌症中心(亚利桑那大学 亚利桑那州)参与西南肿瘤学小组合作癌症 改善人类癌症治疗的临床研究。特定的 目的和目标是： 1.继续满足我们目前的科学领导和核心服务 承诺包括：(A)议定书协调(多项研究)：(B) 疾病/纪律委员会管理；(c参考资料和资料库 实验室管理；(D)集团质量保证和质量 控制力。 2.继续推动有前途的新研究的快速整合 线索，包括亚利桑那州癌症中心开发的线索， 合作团体测试，以改善患者的治疗选择和 病人护理。 3.继续履行我们的机构临床研究承诺 为SWOG研究和ALL招募合适的患者 随之而来的对长期跟踪、质量控制等的承诺。 4.继续提高社区医生和病人的意识和 参与SWOG临床试验继续支持 合作团体外展计划(CGOP)和其他外展和 继续教育计划和活动。 5.继续努力了解影响应计项目的因素， 特别是那些特殊人群(如少数民族、老年人、 经济困难)，并采取适当的干预措施 在可能的情况下。